Xyall, a global innovator in molecular pathology, has attracted a Series B investment of six million Euros to accelerate commercialisation of its Tissector High Throughput and Tissector Table Top systems.
Xyall’s technology enables molecular pathology laboratories to fully automate their tumor tissue dissection workflow. It’s first solution, the Tissector High Throughput System, aimed at large molecular laboratories, was launched in 2021. Xyall has already sold several high-throughput systems to large commercial laboratories in the United States, with the first becoming fully operational from March this year.
Later this year, Xyall launches its compact Tissector Table Top System for hospital-based molecular pathology laboratories. This will be unveiled in November this year at the Annual Molecular Pathology (AMP) meeting in Phoenix, USA, with laboratories worldwide already expressing interest.
While molecular diagnostics has seen advances in PCR and next-generation sequencing technology, selecting tumour tissue and cell samples for molecular diagnostic testing has stayed a manual, labour-intensive step with a risk of error and cross-contamination.
Xyall’s solutions are based on the unique technologies the company has developed in the areas of precision movement, medical robotics and image registration. It addresses the need for accuracy, speed and ease of use in an automated system to make the most efficient use of existing staffing levels.
